Investment Analysts’ Recent Ratings Changes for Legend Biotech (LEGN)

A number of research firms have changed their ratings and price targets for Legend Biotech (NASDAQ: LEGN):

• 9/16/2026 – Legend Biotech was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/11/2026 – Legend Biotech had its price target lowered by Barclays PLC from $78.00 to $74.00. They now have an “overweight” rating on the stock.
• 9/4/2026 – Legend Biotech was given a new $65.00 price target by Morgan Stanley.
• 9/4/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
• 9/1/2026 – Legend Biotech was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/18/2026 – Legend Biotech was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/12/2026 – Legend Biotech had its price target raised by Morgan Stanley from $48.00 to $49.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Legend Biotech was downgraded by Oppenheimer Holdings, Inc. from “outperform” to “market perform”. They now have a $40.00 price target on the stock, down from $75.00.
• 8/12/2026 – Legend Biotech had its price target lowered by Barclays PLC from $80.00 to $78.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Legend Biotech had its price target lowered by TD Cowen from $29.00 to $24.00. They now have a “hold” rating on the stock.
• 8/12/2026 – Legend Biotech had its price target lowered by Royal Bank Of Canada from $59.00 to $58.00. They now have an “outperform” rating on the stock.
• 8/12/2026 – Legend Biotech had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $40.00 price target on the stock, down from $75.00.
• 7/30/2026 – Legend Biotech was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/28/2026 – Legend Biotech had its “buy” rating reaffirmed by Benchmark Co..
• 7/28/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
• 7/27/2026 – Legend Biotech had its “neutral” rating reaffirmed by UBS Group AG. They now have a $28.00 price target on the stock, down from $49.00.
• 7/27/2026 – Legend Biotech had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $58.00 price target on the stock.
• 7/27/2026 – Legend Biotech had its price target lowered by Royal Bank Of Canada from $63.00 to $59.00. They now have an “outperform” rating on the stock.
• 7/24/2026 – Legend Biotech was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $28.00 price target on the stock, down from $49.00.

Insider Buying and Selling

In other Legend Biotech news, CEO Ying Huang sold 5,566 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $14.78, for a total transaction of $82,265.48. Following the completion of the sale, the chief executive officer owned 241,872 shares of the company’s stock, valued at approximately $3,574,868.16. This represents a 2.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.02% of the stock is owned by insiders.

Legend Biotech Corporation (NASDAQ: LEGN) is a global biotechnology company focused on developing, manufacturing and commercializing novel cell therapies for the treatment of cancer and other serious diseases. The company’s work centers primarily on chimeric antigen receptor T-cell (CAR-T) therapies designed to harness a patient’s immune system to recognize and attack cancer cells.

Legend Biotech’s lead product is CARVYKTI (ciltacabtagene autoleucel), a B-cell maturation antigen (BCMA)-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma.